样式: 排序: IF: - GO 导出 标记为已读
-
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic–Intraosseous Administration Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-11-24 Adam Niezgoda, Grzegorz Biegański, Jacek Wachowiak, Jarosław Czarnota, Krzysztof Siemionow, Ahlke Heydemann, Anna Ziemiecka, Maria H. Sikorska, Katarzyna Bożyk, Maria Siemionow
-
Expression of Angiopoietin-2 in Lung Tissue of Juvenile SD Rats with Lipopolysaccharide-Induced Acute Lung Injury and the Role of Ulinastatin Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-10-26 Junying Qiao, Shanshan Guo, Xianjie Huang, Luodan Zhang, Fan Li, Yazhen Fan
-
Prolonged Exposure to High Glucose Induces Premature Senescence Through Oxidative Stress and Autophagy in Retinal Pigment Epithelial Cells Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-08-28 Chien-Chih Chiu, Kai-Chun Cheng, Yi-Hsiung Lin, Chen-Xi He, Yung-Ding Bow, Chia-Yang Li, Chang-Yi Wu, Hui-Min David Wang, Shwu-Jiuan Sheu
-
Improved Production of Anti-FGF-2 Nanobody Using Pichia pastoris and Its Effect on Antiproliferation of Keratinocytes and Alleviation of Psoriasis Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-08-26 Zhenlong Zhou, Baixin Liao, Shengli Wang, Jian Tang, Hui Zhao, Mingjie Tong, Keting Li, Sheng Xiong
-
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-08-11 Yu Cao, Sergey K. Efetov, Mingze He, Yu Fu, Narasimha M. Beeraka, Jin Zhang, Xinliang Zhang, Namitha Bannimath, Kuo Chen
-
In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-07-07 Marta Śledź, Alicja Wojciechowska, Radosław Zagożdżon, Beata Kaleta
-
Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-07-06 Jhon Jairo Calderon, Karol Prieto, Paola Lasso, Susana Fiorentino, Alfonso Barreto
-
Antioxidant and Anti-inflammatory Effects of α-Lipoic Acid on Lipopolysaccharide-induced Oxidative Stress in Rat Kidney Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-06-28 Beata Skibska, Ewa Kochan, Andrzej Stanczak, Anna Lipert, Agnieszka Skibska
-
Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease? Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-06-21 Azza Salamony, Yara Shamikh, Khaled Amer, Tarek Elnagdy, Mostafa Elnakib, Abd Allah Yehia, Wael Hassan, Maha Abdelsalam
Many factors have been implicated in the pathogenesis and severity of COVID-19 pandemic. A wide variation in the susceptibility for SARS-CoV-2 infection among different population, gender and age has been observed. Multiple studies investigated the relationship between the antibody’s titre of previously vaccinated individuals and the susceptibility of coronavirus infection, to find a rapid effective
-
The Pyroptotic and Nonpyroptotic Roles of Gasdermins in Modulating Cancer Progression and Their Perspectives on Cancer Therapeutics Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-05-31 Sheng-Kai Hsu, Yi-En Chen, En-De Shu, Ching-Chung Ko, Wen-Tsan Chang, I.-Ling Lin, Chia-Yang Li, Rovelyn P. Gallego, Chien-Chih Chiu
-
Investigation of the Immunogenic Properties of Ovalbumin Modified by Urban Airborne Particulate Matter Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-05-28 Bernadeta Nowak, Anna Wądołek, Olga Mazuryk, Anna Poznańska, Katarzyna Majzner, Grzegorz Majka, Maria Oszajca, Małgorzata Barańska, Grażyna Stochel, Janusz Marcinkiewicz
-
Omics are Getting Us Closer to Understanding IgA Nephropathy Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-04-15 Krzysztof Mucha, Michał Pac, Leszek Pączek
-
Mast Cells and Resistance to Immunotherapy in Cancer Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-04-11 Domenico Ribatti
-
Effect of Hematopoietic Stem Cell Transplantation and Post-Transplantation Cyclophosphamide on the Microglia Phenotype in Rats with Experimental Allergic Encephalomyelitis Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-03-24 Kaja Kasarełło, Martyna Seta, Dorota Sulejczak, Emilian Snarski, Agnieszka Cudnoch-Jędrzejewska
-
Activating NKG2C Receptor: Functional Characteristics and Current Strategies in Clinical Applications Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-03-10 Jagoda Siemaszko, Aleksandra Marzec-Przyszlak, Katarzyna Bogunia-Kubik
-
The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-02-28 Mohammadamin Sadeghdoust, Farnaz Aligolighasemabadi, Tania Dehesh, Nima Taefehshokr, Adel Sadeghdoust, Katarzyna Kotfis, Amirhossein Hashemiattar, Amir Ravandi, Neda Aligolighasemabadi, Omid Vakili, Beniamin Grabarek, Rafał Staszkiewicz, Marek J. Łos, Pooneh Mokarram, Saeid Ghavami
-
A Comprehensive Study on the Anti-cancer Effects of Quercetin and Its Epigenetic Modifications in Arresting Progression of Colon Cancer Cell Proliferation Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-02-20 Meenu Bhatiya, Surajit Pathak, Ganesan Jothimani, Asim K. Duttaroy, Antara Banerjee
-
Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-02-21 Katarzyna Kapten, Krzysztof Orczyk, Elzbieta Smolewska
-
Heterogeneity of Extracellular Vesicles and Particles: Molecular Voxels in the Blood Borne “Hologram” of Organ Function, Disfunction and Cancer Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-02-02 Janusz Rak, Leon Strzadala
-
Ly-6A-Induced Growth Inhibition and Cell Death in a Transformed CD4+ T Cell Line: Role of Tumor Necrosis Factor-α Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-02-01 Akshay G. Patel, Sarah Moxham, Anil K. Bamezai
-
Stress-Sensitive Regulators of Fetal Neurodevelopment in HIV and Preeclampsia: An Immunocytochemical Appraisal of Placental OGT and T4 Levels Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2023-01-21 Philemon D. Shallie, Thajasvarie Naicker, Nihar R. Nayak
-
An Assessment of the Serum Activity of ADH and ALDH in Patients with Primary Biliary Cholangitis Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-12-28 Blanka Wolszczak-Biedrzycka, Anna Bieńkowska, Elżbieta Zasimowicz, Grzegorz Biedrzycki, Justyna Dorf, Wojciech Jelski
Primary biliary cholangitis (PBC; previously known as primary biliary cirrhosis) is a chronic inflammation-induced cholestatic process in the liver. Antimitochondrial antibodies (AMAs) are observed in around 90% of patients, which suggests that PBC is an autoimmune disease. Alcohol dehydrogenase (ADH), ADH isoenzymes and aldehyde dehydrogenase (ALDH) are localized in the liver, and they are useful
-
Impact of Betamethasone Pretreatment on Engrafment of Cord Blood-Derived Hematopoietic Stem Cells Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-12-18 David Perna-Barrull, Laia Gomez-Muñoz, Silvia Rodriguez-Fernandez, Anna Gieras, Rosa M. Ampudia-Carrasco, Lidia Almenara-Fuentes, Ruth M. Risueño, Sergi Querol, Eva Tolosa, Marta Vives-Pi
-
Application of Metabolomics in Childhood Leukemia Diagnostics Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-11-07 Agata Kozioł, Małgorzata Pupek
-
Small Extracellular Vesicles Loaded with Immunosuppressive miRNAs Leads to an Inhibition of Dendritic Cell Maturation Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-11-01 Liliana Czernek, Łukasz Pęczek, Markus Düchler
-
What Has Immunology Brought to Periodontal Disease in Recent Years? Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-10-16 Jan Kowalski, Maciej Nowak, Bartłomiej Górski, Renata Górska
Recent decades have shed a new light on the pathomechanism of periodontal inflammation. While classic periodontology concentrates on biofilm control, oral hygiene improvement, professional tooth cleaning and surgical correction of damaged periodontal tissues, new aspects of the destruction mechanisms are being raised. Among them, the greatest attention is paid to the influence of host response on the
-
Interleukin-35 has a Protective Role in Infectious Mononucleosis-Induced Liver Inflammation Probably by Inhibiting CD8+ T Cell Function Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-10-11 Ying Gao, Lan Li, Xingxing Hu, Weihua Zhang, Yu Li
-
Bisphenol A: Potential Factor of Miscarriage in Women in the Context of the Phenomenon of Neutrophil Extracellular Traps Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-10-01 Wioleta Justyna Omeljaniuk, Angelika Edyta Charkiewicz, Marzena Garley, Wioletta Ratajczak-Wrona, Jan Czerniecki, Ewa Jabłońska, Marzanna Cechowska-Pasko, Wojciech Miltyk
-
Angiotensin II Type 1 Receptor Antibodies Are Higher in Lupus Nephritis and Vasculitis than Other Glomerulonephritis Patients Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-09-24 Maciej Szymczak, Harald Heidecke, Marcelina Żabińska, Dagna Rukasz, Krzysztof Wiśnicki, Andrzej Tukiendorf, Magdalena Krajewska, Mirosław Banasik
Angiotensin II type 1 receptor (AT1R) antibodies are considered non-HLA (human leukocyte antigen) antibodies connected with humoral rejection after kidney transplantation. The role of AT1R antibodies in the pathogenesis of glomerular diseases and systemic vasculitis is unknown. We assessed the level of AT1R antibodies in 136 patients with different types of glomerulonephritis and systemic vasculitis
-
Correction to: CD5L Secreted by Macrophage on Atherosclerosis Progression Based on Lipid Metabolism Induced Inflammatory Damage Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-09-24 Liang Wang, Lijuan Liu, Wei Qian, Zeqi Zheng
-
Monitoring of Soluble Forms of BAFF System (BAFF, APRIL, sR-BAFF, sTACI and sBCMA) in Kidney Transplantation Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-09-22 Rafael Alfaro, Santiago Llorente, Pedro Martinez, Víctor Jimenez-Coll, Helios Martínez-Banaclocha, José Antonio Galián, Carmen Botella, María Rosa Moya-Quiles, Jesús de la Peña-Moral, Alfredo Minguela, Isabel Legaz, Manuel Muro
-
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-08-17 Maria Siemionow, Sonia Brodowska, Paulina Langa, Kristina Zalants, Katarzyna Kozlowska, Wictoria Grau-Kazmierczak, Ahlke Heydemann
-
Immunotherapy in Ovarian Cancer Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-08-09 Natalia Siminiak, Rafał Czepczyński, Mikołaj Piotr Zaborowski, Dariusz Iżycki
-
Elevated Levels of Soluble CD147 are Associated with Hyperinflammation and Disease Severity in COVID-19: A Proof-of-Concept Clinical Study Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-08-03 Rashidi Springall, Julieta González-Flores, Carlos García-Ávila, Yaneli Juárez-Vicuña, Adrián Hernández-Diazcouder, Ricardo Márquez-Velasco, Sergio Cásares-Alvarado, Fausto Sánchez-Muñoz, Edna Basilio-Gálvez, Mauricio Castillo-Salazar, Martha A. Ballinas-Verdugo, Malinalli Brianza-Padilla, José L. Sánchez-Gloria, Claudia Tavera-Alonso, Julio Sandoval, Héctor González-Pacheco, Luis M. Amezcua-Guerra
-
The Effect of Inhaled Air Particulate Matter SRM 1648a on the Development of Mild Collagen-Induced Arthritis in DBA/J Mice Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-07-28 Bernadeta Nowak, Grzegorz Majka, Małgorzata Śróttek, Anna Skałkowska, Janusz Marcinkiewicz
-
Sex Differences in Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer’s Disease Patients Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-06-16 Marta Sochocka, Michał Ochnik, Maciej Sobczyński, Beata Orzechowska, Jerzy Leszek
-
Transcriptome Studies in Lupus Nephritis Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-04-25 Marta E. Alarcón-Riquelme
-
Hydroxychloroquine Therapy and Serum Immunoglobulin Levels in Women with IgG Subclass Deficiency and Systemic Lupus Erythematosus, Sjögren Syndrome, and Rheumatoid Arthritis: A Retrospective Study Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-04-11 James C. Barton, J. Clayborn Barton, Luigi F. Bertoli
Hydroxychloroquine (HCQ) therapy decreased immunoglobulin (Ig) levels in patients with Sjögren syndrome (SS) and rheumatoid arthritis (RA) in previous studies. We found no report of Ig levels of women with IgG subclass deficiency (IgGSD) and systemic lupus erythematosus (SLE), SS, or RA treated with HCQ. We retrospectively evaluated IgG, IgG subclass, IgA, and IgM levels and other characteristics of
-
Preliminary Results for Personalized Therapy in Pregnant Women with Polycystic Ovary Syndrome During the COVID-19 Pandemic Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-03-24 Małgorzata Jerzak, Monika Szafarowska
Increased androgen level, hyperinsulinemia, diabetes, impaired fibrinolysis, obesity, hypertension, chronic inflammation, abnormal immune response to infections and hyperhomocysteinemia are the most common abnormalities related to polycystic ovary syndrome (PCOS) women and are the factors predisposing to the severe course of COVID-19. The SARS-Cov-2 infection during pregnancy is associated with an
-
Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-Naïve Early Arthritis Patients Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-03-18 Oscar J. Cordero, Irene Viéitez, Irene Altabás, Laura Nuño-Nuño, Alejandro Villalba, Marta Novella-Navarro, Diana Peiteado, María-Eugenia Miranda-Carús, Alejandro Balsa, Rubén Varela-Calviño, Iria Gomez-Tourino, José M. Pego-Reigosa
In rheumatoid arthritis (RA), the identification of biomarkers to adjust treatment intensity and to correctly diagnose the disease in early stages still constitutes a challenge and, as such, novel biomarkers are needed. We proposed that autoantibodies (aAbs) against CD26 (DPP4) might have both etiological importance and clinical value. Here, we perform a prospective study of the potential diagnostic
-
New Treatment Options in Lupus Nephritis Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-03-17 Pauline M. Montigny, Frédéric A. Houssiau
The aim of this study is to report major recent progresses in the treatment of lupus nephritis (LN). Results of controlled randomized trials are discussed in view of the unmet needs in the field. Current treatments of LN are not satisfactory, with a disappointing proportion of 20–30% of patients achieving complete renal response within 6–12 months, and 5–20% developing end-stage kidney disease within
-
CD5L Secreted by Macrophage on Atherosclerosis Progression Based on Lipid Metabolism Induced Inflammatory Damage Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-03-06 Liang Wang, Lijuan Liu, Wei Qian, Zeqi Zheng
To explore the molecular mechanism of exosomal protein CD5L secreted by macrophage to promote the progression of atherosclerosis. Twenty cases of patients with atherosclerosis (AS) and 20 cases of healthy subjects were collected. Morphological properties of exosomes were identified by transmission electron microscopy, and the marker proteins CD63 and CD81 of exosomes were measured by Western blot.
-
Recombinant Human Lactoferrin Reduces Inflammation and Increases Fluoroquinolone Penetration to Primary Granulomas During Mycobacterial Infection of C57Bl/6 Mice Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-02-28 Thao K. T. Nguyen, Zainab Niaz, Marian L. Kruzel, Jeffrey K. Actor
Infection with Mycobacterium tuberculosis (Mtb) results in the primary formation of a densely packed inflammatory foci that limits entry of therapeutic agents into pulmonary sites where organisms reside. No current therapeutic regimens exist that modulate host immune responses to permit increased drug penetration to regions of pathological damage during tuberculosis disease. Lactoferrin is a natural
-
Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy? Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-02-11 Ioannis Parodis, Farah Tamirou, Frédéric A. Houssiau
Kidney involvement, termed lupus nephritis (LN), develops in 35–60% of patients with systemic lupus erythematosus, often early during the disease course. When not treated promptly and efficiently, LN may lead to rapid and severe loss of kidney function, being the reason why it is considered one of the most severe lupus manifestations. Despite improved pharmacotherapy, 5–20% of LN patients develop end-stage
-
The Role of Gut Microbiota in Gastrointestinal Tract Cancers Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-02-03 Marta Grochowska, Karol Perlejewski, Tomasz Laskus, Marek Radkowski
Disturbances in gastrointestinal (GI) microbiota could play a significant role in the development of GI cancers, but the underlying mechanisms remain largely unclear. While some bacteria seem to facilitate carcinogenesis, others appear to be protective. So far only one bacterium (Helicobacter pylori) has been classified by the International Agency for Cancer Research as carcinogenic in humans but many
-
Effects of Local Nasal Immunotherapy with FIP-fve Peptide and Denatured Tyrophagus putrescentiae for Storage Mite-Induced Airway Inflammation Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-01-31 Chung-Yang Yen, Ching-Hsiang Yu, Jaw-Ji Tsai, Hsiang-Kuang Tseng, En-Chih Liao
Allergic diseases are affecting public health and have increased over the last decade. Sensitization to mite allergens is a considerable trigger for allergy development. Storage mite-Tyrophagus putrescentiae shows great significance of allergenic potential and clinical relevance. The fungal immunomodulatory peptide FIP-fve has been reported to possess immunomodulatory activity. We aimed to determine
-
The Role of Immunoproteasomes in Tumor-Immune Cell Interactions in Melanoma and Colon Cancer Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-01-22 Leister, Hanna, Krause, Felix F., Mahdavi, Rouzbeh, Steinhoff, Ulrich, Visekruna, Alexander
The participation of proteasomes in vital cellular and metabolic processes that are involved in tumor growth has made this protease complex an attractive target for cancer treatment. In contrast to ubiquitously available constitutive proteasome, the increased enzymatic activity of immunoproteasome is associated with tumor-infiltrating immune cells, such as antigen-presenting cells and T lymphocytes
-
Rho Kinases in Embryonic Development and Stem Cell Research Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2022-01-19 Shi, Jianjian, Wei, Lei
The Rho-associated coiled-coil containing kinases (ROCKs or Rho kinases) belong to the AGC (PKA/PKG/PKC) family of serine/threonine kinases and are major downstream effectors of small GTPase RhoA, a key regulator of actin-cytoskeleton reorganization. The ROCK family contains two members, ROCK1 and ROCK2, which share 65% overall identity and 92% identity in kinase domain. ROCK1 and ROCK2 were assumed
-
Peroxiredoxins as Markers of Oxidative Stress in IgA Nephropathy, Membranous Nephropathy and Lupus Nephritis Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-12-16 Krata, Natalia, Foroncewicz, Bartosz, Zagożdżon, Radosław, Moszczuk, Barbara, Zielenkiewicz, Magdalena, Pączek, Leszek, Mucha, Krzysztof
IgA nephropathy (IgAN), membranous nephropathy (MN), and lupus nephritis (LN) represent important causes of chronic kidney disease. They belong to the immune-mediated glomerulonephritis (GNs), and have distinct pathogenesis, distinct clinical courses, and variable responses to treatment. Therefore, specific diagnostic procedures are necessary for more effective patient management. Recently, a role
-
Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-12-12 Mazza, Roberta, Maher, John
Technologies required to generate induced pluripotent stem cells (iPSC) were first described 15 years ago, providing a strong impetus to the field of regenerative medicine. In parallel, immunotherapy has finally emerged as a clinically meaningful modality of cancer therapy. In particular, impressive efficacy has been achieved in patients with selected haematological malignancies using ex vivo expanded
-
AITE Celebrates Its 70th Year of Publication (1953-2022). Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-12-09 Hubert Krotkiewski,Michał Zimecki,Andrzej Górski
-
A Novel Human Recombinant Lactoferrin Inhibits Lung Adenocarcinoma Cell Growth and Migration with No Cytotoxic Effect on Normal Human Epithelial Cells Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-11-08 Olszewska, Paulina, Pazdrak, Barbara, Kruzel, Marian L.
Lung cancer remains the leading cause of cancer death worldwide. Despite the recent advances in cancer treatment, only a subset of patients responds to targeted and immune therapies, and many patients developing resistance after an initial response. Lactoferrin (Lf) is a natural glycoprotein with immunomodulatory and anticancer activities. We produced a novel recombinant human Lf (rhLf) that exhibits
-
Immunology and Donor-Specific Antibodies in Corneal Transplantation Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-11-06 Major, Joanna, Foroncewicz, Bartosz, Szaflik, Jacek Paweł, Mucha, Krzysztof
The first human corneal transplantation was performed in 1905 by Eduard Zirm in the Olomouc Eye Clinic, now Czech Republic. However, despite great advancements in microsurgical eye procedures, penetrating keratoplasty in high-risk patients (e.g., vascularized or inflamed corneal tissue, consecutive transplants) remains a challenge. The difficulty is mainly due to the risk of irreversible allograft
-
Differential Leukocyte MicroRNA Responses Following Pan T Cell, Allorecognition and Allosecretome-Based Therapeutic Activation Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-10-22 Yang, Xining, Toyofuku, Wendy M., Scott, Mark D.
Effective immunomodulation of T-cell responses is critical in treating both autoimmune diseases and cancer. Our previous studies have demonstrated that secretomes derived from control or methoxypolyethylene glycol mixed lymphocyte alloactivation assays exerted potent immunomodulatory activity that was mediated by microRNAs (miRNA). The immunomodulatory effects of biomanufactured miRNA-based allo-secretome
-
Molecular Genetics Diversity of Primary Hemophagocytic Lymphohistiocytosis among Polish Pediatric Patients Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-10-22 Bąbol-Pokora, Katarzyna, Wołowiec, Magdalena, Popko, Katarzyna, Jaworowska, Aleksandra, Bryceson, Yenan T., Tesi, Bianca, Henter, Jan-Inge, Młynarski, Wojciech, Badowska, Wanda, Balwierz, Walentyna, Drabko, Katarzyna, Kałwak, Krzysztof, Maciejka-Kembłowska, Lucyna, Pieczonka, Anna, Sobol-Milejska, Grażyna, Kołtan, Sylwia, Malinowska, Iwona
Hemophagocytic lymphohistiocytosis (HLH) is a clinical syndrome of life-threatening inflammation caused by an excessive, prolonged and ineffective immune response. An increasing number of HLH cases is recognized in Poland, but the genetic causes of familial HLH (FHL) have not been reported. We investigated the molecular genetics and associated outcomes of pediatric patients who met HLH criteria. We
-
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-10-12 Hope, Helen Carrasco, Salmond, Robert J.
T cell activation, differentiation and proliferation is dependent upon and intrinsically linked to a capacity to modulate and adapt cellular metabolism. Antigen-induced activation stimulates a transcriptional programme that results in metabolic reprogramming, enabling T cells to fuel anabolic metabolic pathways and provide the nutrients to sustain proliferation and effector responses. Amino acids are
-
The Positive Impact of Donor Bone Marrow Cells Transplantation into Immunoprivileged Compartments on the Survival of Vascularized Skin Allografts Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-10-11 Jundziłł, Arkadiusz, Klimczak, Aleksandra, Sonmez, Erhan, Brzezicki, Grzegorz, Siemionow, Maria
Using the vascularized skin allograft (VSA) model, we compared the tolerogenic effects of different allogeneic bone marrow transplantation (BMT) delivery routes into immunoprivileged compartments under a 7-day protocol immunosuppressive therapy. Twenty-eight fully MHC mismatched VSA transplants were performed between ACI (RT1a) donors and Lewis (RT11) recipients in four groups of seven animals each
-
Cyclosporine A, in Contrast to Rapamycin, Affects the Ability of Dendritic Cells to Induce Immune Tolerance Mechanisms Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-10-10 Machcińska, Maja, Kotur, Monika, Jankowska, Aleksandra, Maruszewska-Cheruiyot, Marta, Łaski, Artur, Kotkowska, Zuzanna, Bocian, Katarzyna, Korczak-Kowalska, Grażyna
Following organ transplantation, it is essential that immune tolerance is induced in the graft recipient to reduce the risk of rejection and avoid complications associated with the long-term use of immunosuppressive drugs. Immature dendritic cells (DCs) are considered to promote transplant tolerance and may minimize the risk of graft rejection. The aim of the study was to evaluate the effects of immunosuppressive
-
Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-09-18 Siri, Morvarid, Behrouj, Hamid, Dastghaib, Sanaz, Zamani, Mozhdeh, Likus, Wirginia, Rezaie, Sedigheh, Hudecki, Jacek, Khazayel, Saeed, Łos, Marek J., Mokarram, Pooneh, Ghavami, Saeid
-
Are Host Defense Peptides and Their Derivatives Ready to be Part of the Treatment of the Next Coronavirus Pandemic? Arch. Immunol. Ther. Exp. (IF 3.2) Pub Date : 2021-09-16 Rivas-Santiago, Bruno, Jacobo-Delgado, Yolanda, Rodriguez-Carlos, Adrian
The term host defense peptides arose at the beginning to refer to those peptides that are part of the host’s immunity. Because of their broad antimicrobial capacity and immunomodulatory activity, nowadays, they emerge as a hope to combat resistant multi-drug microorganisms and emerging viruses, such as the case of coronaviruses. Since the beginning of this century, coronaviruses have been part of different